Literature DB >> 21049829

Factors that influence adherence and strategies to maintain adherence to injected therapies for patients with multiple sclerosis.

Carol Saunders1, Christina Caon, Jennifer Smrtka, Jennifer Shoemaker.   

Abstract

A key aspect of the management of care for patients with multiple sclerosis (MS) is identifying which patients are struggling with adherence. Disease-modifying therapies for the treatment of MS are primarily preventative, with modest efficacy, and they can possibly cause significant side effects. These factors can lead patients to stop taking their medication because they continue to experience symptoms or relapses of the disease, and/or they have painful injection-site reactions on most parts of their bodies. However, striving for 100% adherence to the prescribed treatment regimen remains the goal and is the surest way to reap all the benefits associated with immunomodulatory therapy. Building trust, promoting injection self-efficacy, and educating patients about proper injection techniques to prevent injection-site reactions have the greatest impact on patient adherence. Factors including family involvement, financial stability and support, hope, and faith can also have a positive impact on adherence. Identifying patients who may be struggling with depression, which is easily treatable but often not well addressed, and providing access to mental health services are important. Although many strides have been made with regard to MS patient care, outlining strategies that can maintain or encourage adherence can provide practitioners with tools to facilitate their patients' health and well-being.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21049829     DOI: 10.1097/jnn.0b013e3181ee122b

Source DB:  PubMed          Journal:  J Neurosci Nurs        ISSN: 0888-0395            Impact factor:   1.230


  12 in total

1.  The Combined Effect of Nursing Support and Adverse Event Mitigation on Adherence to Interferon Beta-1b Therapy in Early Multiple Sclerosis: The START Study.

Authors:  Suhayl Dhib-Jalbut; Clyde Markowitz; Payal Patel; Francis Boateng; Mark Rametta
Journal:  Int J MS Care       Date:  2012

Review 2.  Multiple sclerosis in men: management considerations.

Authors:  Riley Bove; Allison McHenry; Kerstin Hellwig; Maria Houtchens; Neda Razaz; Penelope Smyth; Helen Tremlett; A D Sadovnick; D Rintell
Journal:  J Neurol       Date:  2016-01-02       Impact factor: 4.849

3.  Self-efficacy as a longitudinal predictor of perceived cognitive impairment in individuals with multiple sclerosis.

Authors:  Abbey J Hughes; Meghan Beier; Narineh Hartoonian; Aaron P Turner; Dagmar Amtmann; Dawn M Ehde
Journal:  Arch Phys Med Rehabil       Date:  2015-01-15       Impact factor: 3.966

4.  Reliability and validity of a self-efficacy instrument for hepatitis C antiviral treatment regimens.

Authors:  J E Bonner; D Esserman; D M Evon
Journal:  J Viral Hepat       Date:  2011-11-24       Impact factor: 3.728

5.  Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis.

Authors:  Rachel Halpern; Sonalee Agarwal; Carole Dembek; Leigh Borton; Maria Lopez-Bresnahan
Journal:  Patient Prefer Adherence       Date:  2011-01-20       Impact factor: 2.711

6.  Lifestyle factors, demographics and medications associated with depression risk in an international sample of people with multiple sclerosis.

Authors:  Keryn L Taylor; Emily J Hadgkiss; George A Jelinek; Tracey J Weiland; Naresh G Pereira; Claudia H Marck; Dania M van der Meer
Journal:  BMC Psychiatry       Date:  2014-12-03       Impact factor: 3.630

7.  The care continuum in acromegaly: how patients, nurses, and physicians can collaborate for successful treatment experiences.

Authors:  Cynthia Plunkett; Ariel L Barkan
Journal:  Patient Prefer Adherence       Date:  2015-07-30       Impact factor: 2.711

8.  Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study.

Authors:  Deepak M W Balak; Gerald J D Hengstman; Enes Hajdarbegovic; Rob J P van den Brule; Raymond M M Hupperts; Hok Bing Thio
Journal:  BMC Neurol       Date:  2013-10-16       Impact factor: 2.474

Review 9.  Subcutaneous administration of bortezomib: strategies to reduce injection site reactions.

Authors:  Sandra Kurtin; Carol S Knop; Todd Milliron
Journal:  J Adv Pract Oncol       Date:  2012-11

10.  Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device: a prospective open-label Scandinavian noninterventional study (the ScanSmart study).

Authors:  Elena Didenko Pedersen; Egon Stenager; J L Vadgaard; M B Jensen; R Schmid; N Meland; G Magnussen; Jette L Frederiksen
Journal:  Patient Prefer Adherence       Date:  2018-04-19       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.